Back to Search
Start Over
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials
- Source :
- Cancer Science
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- This post hoc analysis of MONARCH 2 and MONARCH 3 assesses the efficacy, safety, and pharmacokinetics (PK) of abemaciclib in combination with endocrine therapy (ET) in East Asian patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2‐negative (HER2−) advanced breast cancer. MONARCH 2 and MONARCH 3 are global, randomized, double‐blind, phase 3 studies of abemaciclib/placebo + fulvestrant and abemaciclib/placebo + nonsteroidal aromatase inhibitor (NSAI, anastrozole or letrozole), respectively. The East Asian population comprised 212 (31.7%) of the 669 intent‐to‐treat (ITT) population in the MONARCH 2 trial and 144 (29.2%) of the 493 ITT patients in the MONARCH 3 trial. In the East Asian population, median progression‐free survival (PFS) was significantly prolonged in the abemaciclib arm compared with placebo in both MONARCH 2 (hazard ratio [HR], 0.520; 95% confidence interval [CI], 0.362 to 0.747; P<br />Abemaciclib in combination with endocrine therapy (ET) in the East Asian populations of MONARCH 2 and MONARCH 3 improved efficacy for patients with HR+, HER2− advanced breast cancer.
- Subjects :
- 0301 basic medicine
Cancer Research
Receptor, ErbB-2
Aminopyridines
abemaciclib
0302 clinical medicine
East Asia
Fulvestrant
education.field_of_study
Aromatase Inhibitors
Letrozole
Hazard ratio
General Medicine
metastatic
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Original Article
Drug Therapy, Combination
Female
medicine.drug
Diarrhea
medicine.medical_specialty
Neutropenia
animal structures
Population
Anastrozole
Breast Neoplasms
Placebo
03 medical and health sciences
breast cancer
Breast cancer
Double-Blind Method
Clinical Research
Internal medicine
medicine
Humans
education
Adverse effect
cyclin‐dependent kinase inhibitor
business.industry
fungi
Original Articles
medicine.disease
030104 developmental biology
Benzimidazoles
business
Subjects
Details
- ISSN :
- 13497006 and 13479032
- Volume :
- 112
- Database :
- OpenAIRE
- Journal :
- Cancer Science
- Accession number :
- edsair.doi.dedup.....bb8743256a997ac6937c64811a20809f